Fuan Pharmaceutical

Fuan Pharmaceutical (Group) Co., Ltd. was established on February 25, 2004, and successfully listed on the Shenzhen ChiNext on March 22, 2011, with a registered capital of 1.189 billion yuan and more than 3,000 employees.
Through a series of mergers and reorganizations, it has grown into a pharmaceutical group company with 11 wholly-owned subsidiaries, integrating R&D, production of intermediates, APIs, and formulations, and domestic and international trade.
In 2019, it was rated as one of China's Top 100 Pharmaceutical Industry Enterprises and one of the most growth-potential enterprises.
In 2020, it was rated as one of Chongqing's Top 100 Manufacturing Enterprises.
In 2020, it was rated as one of China's Top 100 in Comprehensive Pharmaceutical R&D Strength.
In 2020, it was rated as one of China's Top 100 in Chemical Drug R&D Strength.
The company's products cover anti-infection, psycho-neurological, digestive and metabolic, anti-tumor, cardiovascular and cerebrovascular, liver disease and other fields, with 93 patents; 4 API production bases, 25 production lines, an annual comprehensive output of about 1,500 tons, and an annual output value of 1.8 billion yuan; 4 formulation production bases, 18 production lines, and an annual output value of 2.3 billion yuan.
Against the backdrop of global integration, while maintaining its foothold in the field of chemical pharmaceuticals, the company has established a U.S. company and actively expanded its international sector, laying a solid foundation for the group's international development.